France's SpineGuard Q3 revenue falls on distribution model shift

Spineguard SA

08/10/2026 17:10

Overview
France medical device maker's Q3 2026 revenue fell 14% yr/yr to €662K
Company sold 22% more units globally, driven by commercial partnerships
International sales grew 25%, led by Europe, Asia, and the Middle East

Outlook
SpineGuard aims to achieve operating breakeven in the fourth qtr of 2026
Company says it can cover financing needs through the second qtr of 2027
Company is actively pursuing new strategic partnerships and options to strengthen its financial structure

Result Drivers
UNIT SALES GROWTH - Co said global unit sales rose 22% in Q3, driven by commercial partnerships
DISTRIBUTION MODEL SHIFT - Co attributed Q3 revenue decline to transition from direct sales to distribution model in U.S. via Omnia Medical
INTERNATIONAL EXPANSION - Co said international sales grew 25% in Q3, helped by new distributors in UK, Croatia, and Turkey

Company press release: ID:nBw2CWnyda

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
 
EUR 662,000
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Spineguard SA is €0.39, about 336.7% above its October 7 closing price of €0.09

Reuters Recommended Reads
Oct 7 - Medical device maker Centinel Spine discloses revenue rise in US IPO filing
Oct 6 - Stryker taps insider Stiles to succeed industry veteran Lobo as CEO
Oct 6 - Becton Dickinson pledges $19 billion US investment in deal with government

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)